If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, ...
Hosted on MSN
What Are Alveoli?
What these tiny sacs in the lungs do and conditions that can affect them Medically reviewed by Susan Russell, MD Alveoli are tiny, balloon-shaped air sacs located at the end of the bronchioles, the ...
New discovery on the causes of PAP lung disease can also offer solutions for treating obesity and heart disease. The research group of Associate Professor Alexander Mildner at the University of Turku, ...
Description: Effrosyni D. Manali, M.D., Ph.D., Maria Molina-Molina, M.D., Ph.D., and Maria Kokosi, M.D. will provide an update on autoimmune pulmonary alveolar ...
Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The ...
Poster Title: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Session: English Poster Discussion “Rare ...
IMPALA-2 is a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback